Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting

Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting

Pan et al. determine the impact of the antiviral remdesivir (RDV) on biomarkers associated with clinical outcomes, within a randomized, double-blind, placebo-controlled phase 3 study (PINETREE). They demonstrate that RDV-treated patients have an accelerated reduction in soluble angiopoietin-2, D-dim...

Full description

Bibliographic Details
Main Authors: David Z. Pan, Pamela M. Odorizzi, Andre Schoenichen, Mazin Abdelghany, Shuguang Chen, Anu Osinusi, Scott D. Patterson, Bryan Downie, Kavita Juneja, Jeffrey J. Wallin
Format: Article
Language:English
Published: Nature Portfolio 2023-01-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-022-00232-2

Internet

https://doi.org/10.1038/s43856-022-00232-2

Similar Items